Pharmacological composition

FIELD: chemistry, pharmacology.

SUBSTANCE: pharmacological composition for preparing drug forms in form of powder, solution or bandage consists of biocompatible film-generating polymer polyvinylpyrrolidone (Mm 20000), iodine and Novocain, taken in quantities, given in the invention formula. Pharmaceutical composition is intended for processing wound surface and treatment of burns. Composition possesses antiseptic, local anesthetic and wound-healing action.

EFFECT: water-soluble form of medication possesses high anti-burn activity, low cost and long storage term.


The invention relates to chemical-pharmaceutical industry, namely the production of pharmaceutical compositions possessing antiseptic, wound healing and local anesthetic properties. Intended for the manufacture of water-soluble dosage forms and dressing materials used for wound closure in the provision of surgical, combustionengines assistance in the activities of specialists in disaster medicine in rendering medical care in extreme situations. Can be used to treat wounds and burns in all phases of the wound healing process.

Currently, there are many medicinal substances of individual substances and prepared from these compositions used for other dosage forms for use in surgeries, dressings when draining wounds, stop bleeding, prevent infection of the wound.

Has long been the simplest way to handle the wound surface was considered as powder substances of furacin (Fund 42-9408-08). From powder prepared furatsilina alcohol solution with a concentration of 1:1500, treated the wound and bandaged the surface. This tool is an antiseptic preparation of local action.

Other known means for prevention of wound infection and purulent complications operas is effective interventions for the treatment of wounds and infected burns is substance - powder streptocide (Fund 42-0173-3836-03). Assigned to introduction into the wound (dusting and blowing) the smallest sterile powder streptocide (5-15 g) or externally - drawing directly on the affected areas of the powder streptocide. He has a selective bacteriostatic activity against streptococci, meningococci, gonococci, pneumococci, Escherichia coli and some other bacteria.

Closest to the claimed invention is the representative of antiseptic drugs on the Russian market - substance powder yodopiron (Fund 42-0550-6985-05), which is used for solution preparation for external use.

This means it has bactericidal activity against many gram-positive and gram-negative microorganisms, it inherent fungicidal effect. However, all the positive properties of this tool is its main disadvantage is the pain that occurs during the processing of the wound edges, which prevents the healing of burn surface.

The present invention solves the problem of creating a pharmaceutical composition for treatment of wounds and burns, with the combined action: antiseptic, local anesthetic and healing.

The technical result consists in the fact that the claimed vocarstvo is ima form of a drug has a high burn-activity, low cost and long shelf life.

This technical result is achieved by the claimed pharmaceutical composition for the preparation of dosage forms in the form of a powder, solution or bandage consisting of a biocompatible film-forming polymer is polyvinylpyrrolidone and iodine, characterized in that it further includes novocaine in the following ratio of components:

Polyvinylpyrrolidone (Mm 20000)80%

When creating this pharmaceutical composition are taken into account the fact that iodine is a well known drug and is widely used in medicine as a solution of iodine alcohol for local and external use. The complex of iodine with polyvinylpyrrolidone based drug yodopiron with antiseptic due to iodine and wound through polyvinylpyrrolidone action.

The advantage of this composition before analogue is that in its composition a complex of iodine and Novocain with polyvinylpyrrolidone. Matrix polyvinylpyrrolidone holds iodine and novocaine, JV which contributes to their release. Due to the iodine provides antimicrobial, antiseptic, disinfectant, antifungal and Antiprotozoal activities. The use of novocaine provides an analgesic effect. The choice of novocaine due to its well-known local anesthetic properties (Mashkovsky L.D. "Drugs").

Ranozazhivlyayuschee the property of the powder due to the introduction in its composition-molecular compound is polyvinylpyrrolidone, which serves as a matrix for iodine and novocaine and provides transport to the wound.

Finished pharmaceutical composition is a powder having antimicrobial, local anesthetic and wound healing properties.

In the result of the combined action of components of the healing is much faster.

Use this song for the further preparation of dosage forms in the form of a powder, solution or dressings with subsequent application to the wound, when providing first aid treatment for cuts, cracks, ulcers, nonhealing wounds, diaper rash, burns third degree.

The invention is implemented, for example, in burn-drug "Novocom" local actions for external use.

The manufacturer specified the drug occurs in several stages.

The first step is the synthesis of this comp the EU, which in turn consists of several stages: mixing in the mixer powdered polyvinylpyrrolidone with a molecular weight of 20,000 (930 g) finely ground crystals of iodine (60 g) and procaine (200 g) for 1 hour at room temperature. Then is heated in the mixer to a temperature of 75°C for 5 hours and subsequently cooling the mixture in a dark place. Synthesized the drug in appearance is amorphous brown powder. It is easily soluble in water and in ethanol.

To determine the concentration of ingredients in the mixture used titrimetric methods. The quantitative content of the substances meet the requirements of the state Pharmacopoeia of the Russian Federation XI edition.

Pharmaceutical composition for the preparation of dosage forms in the form of a powder, solution or bandage consisting of a biocompatible film-forming polymer is polyvinylpyrrolidone and iodine, characterized in that it further includes novocaine in the following ratio of components:

Polyvinylpyrrolidone (Mm 20000)80%


Same patents:

FIELD: chemistry.

SUBSTANCE: invention relates to compound of formula , where Z stands for phenyl, substituted with 1-5 halogen atoms, selected from fluorine and chlorine; R4 stands for C1-C4-alkyl with linear chain or C3-C4-alkyl with branched chain; or to its pharmaceutically acceptable salt. Invention also relates to pharmaceutical composition, inhibiting prolyl hydroxylase activity, based on said compounds.

EFFECT: obtained are novel compounds and based on them pharmaceutical composition, which can be applied in medicine for treatment of diseases, associated with immune response of organism.

18 cl, 20 dwg, 8 tbl, 13 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to the field of cosmetology, namely to a cosmetic composition for peroral introduction, which contains a combination of lycopene, vitamin C, vitamin E and at least one polyphenol compound, obtained from pine bark, in which the ratio of weight content of polyphenol compound to the sum of weight contents of lycopene, vitamin C and vitamin E constitutes from 0.3 to 0.7, as s single active ingredient.

EFFECT: invention is intended for prevention and/or treatment of wrinkles in the area of eyes and mouth angles, small wrinkles, eye bags and dark circles under eyes.

22 cl, 2 ex, 11 tbl

Wound-healing drug // 2517065

FIELD: chemistry.

SUBSTANCE: invention relates to a wound-healing drug which consists of stearic acid; castor oil; zinc stearate; 70% alcohol extract of a plant collection including oak tree bark, marigold flowers, wild chamomile flowers, nettle leaves, taken in ratio of 1:3:2:1, respectively; Na salts of fatty acids of wool fat; boric acid; vaseline; glycerine; triethanolamine; treated water; vegetable oil; Tipton weed extract; wild rose oil or sea buckthorn oil; 10% propolis oily solution; natural L-amino acid-peptide biocomplex obtained by extracting native paunch manure of ruminants with 2.0-3.0% NaCl solution; purified lanolin and derivatives thereof.

EFFECT: improved bactericidal, anti-inflammatory, regenerating, antioxidant and antimicrobial properties, drug does not have allergic action.

4 ex

FIELD: medicine.

SUBSTANCE: composition contains the bactericidal substance Poviargol in the amount of 2.1-7.0 wt % and zosterin in the amount of 1.1-7.0 wt %.

EFFECT: synergetic action of the ingredients of the composition and promotion of the anti-inflammatory, radio protective, reparative action.

1 ex

FIELD: medicine.

SUBSTANCE: invention refers to using ultradisperse silver-containing systems as anti-inflammatory, anti-exudative and wound-healing agents. The ultradisperse silver-containing systems represent zero-valent silver metal nanocomposites at particle size 10-25 nm stabilised with arabinogalactine and its sulphated derivative. The invention also refers to an agent for wound and burn healing having anti-inflammatory, anti-exudative, wound-healing and antimicrobial activity, comprising said silver nanocomposites as a pharmacologically active substance and additionally containing carbomer, triethanolamine, glycerol or 1,2-propylene glycol and water. The agent is presented in the form of topical hydrophilic gel. The invention also refers to using the above agent for wound and burn healing in an individual in need thereof.

EFFECT: declared invention provides creating the hydrophilic gels of silver nanocomposites that are applicable for wound and burn healing.

3 cl, 8 dwg, 7 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to a topical preparation for contaminated wound healing. The above preparation contains lidocaine hydrochloride 0.1-0.2%, thrombolysin 30-36%, metronidazole 0.25-0.5%, clindamycin 0.3-0.45%, rifampicine 0.45-0.6%, olive oil 10%, sea buckthorn oil 1.5-2.0%, starch 5.1% and silver water.

EFFECT: invention promotes reducing contaminated wound complications, provides the advance of antibacterial active substances through intertissue spaces to the deep tissues with faster pathogenic flora inhibition in a wide range.

2 cl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutics and medicine, namely to a soft dosage form in the form of a topical oily gel used in treating purulent skin infections and containing sodium fusidine, methyluracil (dioxomethyl tetrahydropyrimidine), an oily gel base (mineral oil and polyethylene) and additionally hydroxymethyl quinoxaline dioxide.

EFFECT: developing the preparation for treating purulent wounds, degrees 3-4 burns, decubituses and ulcers, possessing the improved antibacterial effect and regenerative action.

2 cl, 8 ex, 2 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine and may be used for chronic wound and/or wound chamber healing. That is ensured by a multiple coating of a patient's chronic wound and/or wound chamber surface with a composition containing a culture medium conditioned by waste products and growth factors of human mesenchymal stem cells, prepared at the stages of a logarithmic and stationary growth phase of a stable cell culture of mesenchymal stem cells, containing biologically active compounds of low-molecular peptides and cytokines, used for human mesenchymal stem cell culture in vitro.

EFFECT: using the given method enables reducing chronic pyoinflammatory processes in wounds and wound chambers of various geneses in a relatively short time and ensuring a complete healing in the wounds and wound chambers of the volume up to 20 cm2.

17 cl

FIELD: medicine.

SUBSTANCE: what is presented is a group of inventions that refers to medicine, namely dermatology. The methods for improving a cosmetic wound appearance and relieving a scarring process in the skin wounds, as well as the method for activating a wound healing. The methods involve administering a pharmaceutical formulation containing pharmaceutically active relaxin into an individual having a skin wound in the amount effective for wound healing with the improved cosmetic wound appearance in comparison with the healed wound in an untreated individual.

EFFECT: group of invention provides improving the skin wound appearance, relieving the scarring process, ensured by the fact that it has been shown that relaxin reduces the angiogenesis and leads to the early disappearance of the new blood vessels that provides the total reduced blood vessels, respectively less wound redness thereby providing the better cosmetic effect.

20 cl, 15 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry and represents a composition for treating wounds, ulcers, erosions, burns, freeze burns adhesions, as well as infections caused by the gram-positive and gram-negative bacteria Staphylococcus spp., Streptococcus spp., Enterococcus spp., Shigella spp., Escherichia spp., Salmonella spp., Proteus spp., Acinetobacter spp., Citrobacter spp., Pseudomonas spp., Serratia spp., Klebsiella spp., Antracoides spp., Cryptococcus spp., pathogenic fungi of the genera Microsporum, Trichophyton, Nocardia, Aspergillus, yeast-like fungi of the genus Candida (including the multiresistant strains), as well as Actinomycetes and some pathogenic protozoa (Entamoeba histolytica, Trichomonas vaginalis), containing an active ingredient in the form of 0.001-5.0 wt % of collagenase, 0.001-5.0 wt % of lysozyme and/or 0.001-5.0 wt % of sangvitirine, and an carrier in the form of 0.05-1.0 wt % of p-cyclodextrine or liposomes, and acceptable excipients.

EFFECT: invention provides stability and maintained enzymic activity for a long period of time, deep penetration into an affected skin area, potentiated complex antimicrobial and anti-adhesion action.

2 cl, 10 ex, 4 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: there are presented: a composition for treating cancer containing (a) a conjugate containing (i) a polypeptide vector containing an amino acid sequence min. 70% identical to AngioPep-2 (SEQ ID NO: 97); and (ii) paclitaxel or a paclitaxel analogue conjugated with the above polypeptide; (b) an optional tonicity agent; (c) a buffer agent; (d) an excipient; (e) a polyoxyethylene ester of fatty acid; and (f) 0.01-8% DMSO (versions), a method for preparing (versions), a method of treating cancer, a container comprising the above composition, and a kit comprising the container with the above composition.

EFFECT: invention differs by the fact that the declared conjugates (eg ANG 1005) may pass through the hematoencephalic barrier, be characterised by high absorption by the targeted cells, manifest higher stability or be removed from the cell in a lesser degree, while the based compositions may be dissolved in an aqueous solution; they differ by stability and the minimal decomposition at temperatures within the range of 40°C and 50°C.

53 cl, 3 dwg, 28 tbl

FIELD: chemistry.

SUBSTANCE: present invention relates to a method of increasing water solubility of a low-solubility substance used in pharmaceutical products, veterinary pharmaceutical products, cosmeceuticals, cosmetic products, food products, agricultural chemicals etc. The method of increasing water solubility involves depositing a coating of microparticles of a low-solubility calcium compound, e.g. calcium phosphate or calcium carbonate, on the surface of particles of a low-solubility substance using mechanical energy to allow microparticles of the low-solubility calcium compound to penetrate particles of the low-solubility substance used in pharmaceutical products, veterinary pharmaceutical products, cosmeceuticals, cosmetic products, food products, agricultural chemicals etc.

EFFECT: high water solubility of the low-solubility substance.

14 cl, 99 tbl, 8 ex, 20 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed is application of preparation DAM+™ for injection treatment of gastroesophageal reflux (gastroesophageal reflux disease).

EFFECT: described is recovery of locking function of gastroesophageal junction with absence of migration, which contributes to extension of arsenal of medications used for treatment of the disease.

5 dwg, 1 tbl

FIELD: chemistry.

SUBSTANCE: invention relates to chemical-pharmaceutical and food industry and specifically to production of powdered and encapsulated forms of preparations, having antihypoxic and antioxidant action. The molecular complexes are capable of solubilisation in water and are more stable (protected from oxidation) compared to water-insoluble and rapidly oxidisable free reduced coenzyme Q10. Also disclosed is a method of producing said substance, which contains "reduced coenzyme Q10 - β-cyclodextrin" complexes, which comprises consecutive steps of (i) obtaining a reduced form of coenzyme Q10 in the presence of excess ascorbic acid; (ii) mixing the reaction solution obtained at step (i) with aqueous solution of β-cyclodextrin to obtain molecular inclusion complexes; (iii) cooling and crystallising the mixture obtained at step (ii) and removing solvent and water.

EFFECT: substance obtained according to the present invention is a biologically active powdered form of sufficiently stable molecular inclusion complexes of the reduced coenzyme Q10 in β-cyclodextrin with particle size of up to 70-100 mcm, which is tenfold less capable of oxidation compared to free reduced coenzyme Q10 and is easily transferred in an aqueous solution into a solubilised form with particle size of 200-700 nm.

15 cl, 5 ex

FIELD: medicine.

SUBSTANCE: present invention refers to fumaryldiketopiperazine (FDKP) microparticles applicable for pulmonary delivery and having a specific surface area within the range of 15 m2/g to 67 m2/g and a diameter within the range of 0.5 mcm to 10 mcm. The invention also refers to a dry powder comprising said microparticles that is also applicable for pulmonary delivery, to an inhalation system comprising a powder inhalation apparatus and the above dry powder, as well as to a method for delivering an active agent being an ingredient of the dry powder by inhalation of the above dry powder. There are also disclosed methods for forming the FDKP microparticles, first of which comprises dissolving FDKP in aqueous ammonia, adding an acidic solution to aqueous ammonia at temperature up to 12°C to 26°C and collecting a precipitate containing the FDKP microparticles after rinsing with deionised water. A second method for forming the FDKP microparticles involves supplying equal portions of 10.5 wt % of an acetic acid solution and 2.5 wt % of a FDKP solution at temperature 14-18°C through a high-shear mixer.

EFFECT: invention aims at preparing the FDKP microparticles applicable for pulmonary delivery that have the good aerodynamic performance and provide the enhanced drug absorption.

18 cl, 4 tbl, 9 dwg, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to chemical-pharmaceutical industry, particularly to a method for preparing a powder. The method involves the stages of providing at least one first ingredient that has a consistence of viscous fluid and that has an initial melting point within the temperature range of 15°C to 40°C, providing at least one second ingredient that has a melting point, particularly within the range above an ambient temperature up to 120°C, preparing a homogenous liquid mixture containing one first ingredient and one second ingredient by mixing and heating the mixture to a temperature or maintaining a temperature of the mixture within the range above the melting point. Supplying the liquid mixture to an irrigation hardening unit and extracting the powder prepared by irrigation hardening. In addition, the present invention refers to the method for preparing the solid dosage form containing the powder prepared by the method described above.

EFFECT: improvement of the method.

17 cl, 6 ex, 2 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, namely a method for preparing a biologically active complex containing serotonin. The method for preparing the biologically active complex containing serotonin involves milling a herbal raw material that is young sprouts of sea buckthorn collected in the early spring and containing 0.9%-1.1% of serotonin in a cutting mill; mixing the milled herbal raw material and ascorbic acid in a blade mixer; carrying out solid-phase mechanochemical treatment in a roll mill in the intensive mechanical environment in the presence of solid edible agents specified in: citric acid - sodium chloride at a dry substance (1:0.5)-(1:1), or acid, alkaline and phosphate-containing agents to prepare a fine powder at particle size 125 mcm.

EFFECT: ensured simplifying the technology, improving the production rate, as well as higher yield of the end product per a unit of raw material, and providing the chemical production safety.

5 cl, 1 dwg, 5 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine and biotechnology and concerns treating an antibacterial agent for treating gastrointestinal diseases, preferentially acute intestinal infections, including unexplained. The declared preparation represents a mixture of an antibiotic and probiotic, wherein the antibiotic is presented by ofloxacin, while the probiotic is a bifidus bacterial biomass in the following ratio, mg/capsule: ofloxacin - 200 mg, bifidus bacterial biomass - 200 mg containing min. 2×107 CFU/g living microorganisms.

EFFECT: invention enables reducing the length of recovery in the patients suffering acute intestinal infection considerably.

1 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to medicine and pharmaceutical industry and describes an inhalation preparation for treating bronchial asthma and chronic obstructive pulmonary disease, containing micronized budesonide and micronised formoterol fumarate dehydrate as active ingredients, wherein the preparation contains a carrier presented by lactose of average particle diameter 1 to 10 mcm and sodium benzoate of bulk density 0.30-0.50 g/cm3, in the following proportions of the ingredients per a dose of the preparation: budesonide 50 mcg - 800 mcg, formoterol fumarate dehydrate 4.5 mcg - 18 mcg, lactose 5 mg - 50 mg, sodium benzoate 0.01 mg - 5 mg. What is also described is a method for producing the given preparation.

EFFECT: invention provides a higher percentage of a fraction of the active substances and respectively higher effectiveness.

4 cl, 8 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed invention is aimed at pharmaceutical compositions and methods of producing such compositions, where compositions include combination of particles with synchronised impulse release (SIR-particles) and particles with fast release (FR-particles). Each SIR-particle includes core, covered with SIR-layer; core includes weakly basic poorly soluble medicinal substance and pharmaceutically acceptable organic acid, which are separated from each other by layer with delayed release. Each FR-particle includes granule, which contains weakly basic poorly soluble medicinal substance, pharmaceutically acceptable binding substance, at least, one auxiliary substance and, at least, one backing powder. As organic acid, fumaric acid is preferably applied. FR-granules are conjoined with SIR-granules in single pharmaceutical formula, for example, in capsule.

EFFECT: medical form by invention has improved profile of release of weakly basic poorly soluble medicinal substances and is suitable for oral introduction once per day.

32 cl, 11 dwg, 2 tbl, 8 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine and concerns a liquid formulation of a long-acting conjugate of granulocyte colony stimulating factor (G-CSF) containing a therapeutically effective amount of the long-acting conjugate of granulocyte colony stimulating factor wherein G-CSF is covalently bond to immunoglobulin Fc fragment by a non-peptide polymer, and an albumin-free stabilising agent containing a buffer and mannitol.

EFFECT: invention makes the long-acting conjugates of G-CSF having better duration of action and stability in vivo, stay storage-stable for a long period of time.

24 cl, 1 dwg, 16 tbl, 8 ex